Thomas L. Jang

3.6k total citations · 1 hit paper
120 papers, 2.5k citations indexed

About

Thomas L. Jang is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Thomas L. Jang has authored 120 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 50 papers in Surgery and 27 papers in Molecular Biology. Recurrent topics in Thomas L. Jang's work include Prostate Cancer Diagnosis and Treatment (26 papers), Renal cell carcinoma treatment (24 papers) and Bladder and Urothelial Cancer Treatments (24 papers). Thomas L. Jang is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (26 papers), Renal cell carcinoma treatment (24 papers) and Bladder and Urothelial Cancer Treatments (24 papers). Thomas L. Jang collaborates with scholars based in United States, South Korea and China. Thomas L. Jang's co-authors include Paul Russo, William C. Huang, Elena B. Elkin, Andrew S. Levey, Chung Lee, Ximing J. Yang, Irwin Park, Qiang Zhang, Beverly A. Teicher and Scott Lonning and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Thomas L. Jang

112 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Partial Nephrectomy Versus Radical Nephrectomy in Patients With Small Renal Tumors—Is There a Difference in Mortality and Cardiovascular Outcomes?

2008 616 citations Thomas L. Jang et al. The Journal of Urology profile →

Peers

Thomas L. Jang

PRM

SURGE

ONCOL

IMMUN

Alana Christie United States

John M. Corman United States

Jacques Irani France

G. Pignot France

Sima P. Porten United States

Fabien Saint France

Christian Doehn Germany

I. Sinescu Romania

Damian Hanbury United Kingdom

B Debré France

Alana Christie United States

Thomas L. Jang

1.5k ×1.1

PRM

930 ×0.9

577 ×0.9

SURGE

694 ×1.2

ONCOL

125 ×0.4

IMMUN

Citations per year, relative to Thomas L. Jang Thomas L. Jang (= 1×) peers Alana Christie

Countries citing papers authored by Thomas L. Jang

Since Specialization

Citations

This map shows the geographic impact of Thomas L. Jang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas L. Jang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas L. Jang more than expected).

Fields of papers citing papers by Thomas L. Jang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas L. Jang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas L. Jang. The network helps show where Thomas L. Jang may publish in the future.

Co-authorship network of co-authors of Thomas L. Jang

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas L. Jang. A scholar is included among the top collaborators of Thomas L. Jang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas L. Jang. Thomas L. Jang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pfail, John, Arnav Srivastava, David Golombos, et al.. (2025). Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 43(11). 661.e19–661.e28.

Pfail, John, et al.. (2024). MP17-12 IMPACT OF PREFERENCE SIGNAL EXPANSION ON LIKELIHOOD OF INTERVIEW INVITATION IN THE UROLOGY MATCH. The Journal of Urology. 211(5S). 1 indexed citations

Pfail, John, et al.. (2024). Targeted Therapy in Non-Muscle Invasive Bladder Cancer-Clinical Updates. PubMed. 6(1). 43–49.

Sutera, Philip, Jongmyung Kim, Ritesh Kumar, et al.. (2024). PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer. The Prostate. 84(14). 1301–1308. 2 indexed citations

Jang, Thomas L., et al.. (2024). Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors. Journal of Clinical Medicine. 13(23). 7448–7448. 4 indexed citations

Iyer, Hari S., Kevin H. Kensler, Konrad H. Stopsack, et al.. (2023). Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention. 32(8). 1120–1123. 3 indexed citations

Pfail, John, Hiren V. Patel, Sai Krishnaraya Doppalapudi, et al.. (2023). Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer. Urologic Oncology Seminars and Original Investigations. 42(1). 21.e9–21.e20. 3 indexed citations

Pfail, John, Biren Saraiya, Tina Mayer, et al.. (2023). Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?. Current Urology Reports. 24(7). 299–306. 1 indexed citations

Umbehr, Martin, Adrian Wagg, Jodi Antonelli, et al.. (2022). Top Ten Tips Palliative Care Clinicians Should Know About Urological Care. Journal of Palliative Medicine. 26(2). 264–269. 3 indexed citations

10.

Srivastava, Arnav, Hiren V. Patel, Gopal N. Gupta, et al.. (2022). Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars and Original Investigations. 40(4). 169.e1–169.e12. 2 indexed citations

11.

Doppalapudi, Sai Krishnaraya, Joseph Boyle, Kevin Lee Min Chua, et al.. (2022). Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review. Cancers. 14(22). 5644–5644. 1 indexed citations

12.

Patel, Hiren V., Joshua Sterling, Arnav Srivastava, et al.. (2022). The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass. Urology. 168. 122–128. 1 indexed citations

13.

Patel, Hiren V., Sinae Kim, Arnav Srivastava, et al.. (2022). Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(3). 296–296.e9. 11 indexed citations

14.

Patel, Hiren V., Arnav Srivastava, Sinae Kim, et al.. (2022). Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. The Journal of Urology. 207(5). 1057–1066. 6 indexed citations

15.

Kim, Isaac Yi, Antonina Mitrofanova, Sukanya Panja, et al.. (2022). Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate International. 10(2). 75–79. 8 indexed citations

16.

Kim, Isaac Yi, Thomas L. Jang, Sinae Kim, et al.. (2021). Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine. 10(22). 7909–7920. 4 indexed citations

17.

Sterling, Joshua, Zorimar Rivera‐Núñez, Hiren V. Patel, et al.. (2020). Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care. Clinical Genitourinary Cancer. 18(6). e643–e650. 7 indexed citations

18.

Tan, Xiang‐Lin, E Jian‐Yu, Yong Lin, et al.. (2020). Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine. 9(7). 2379–2389. 23 indexed citations

19.

Srivastava, Arnav, Zorimar Rivera‐Núñez, Sinae Kim, et al.. (2020). Impact of pathologic lymph node‐positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer. Cancer. 126(13). 2991–3001. 22 indexed citations

20.

Zhang, Qiang, Brian T. Helfand, Thomas L. Jang, et al.. (2009). Nuclear Factor-κB-Mediated Transforming Growth Factor-β-Induced Expression of Vimentin Is an Independent Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research. 15(10). 3557–3567. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact